{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG000","lowerLimit":"7.5","upperLimit":"NA","value":"17.6"},{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG001","lowerLimit":"2.90","upperLimit":"NA","value":"24.3"},{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG002","lowerLimit":"14.3","upperLimit":"NA","value":"29.2"},{"groupId":"OG003","lowerLimit":"7.7","upperLimit":"15.4","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"TTP defined as time from first dose to first documented confirmed progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG000","title":"A (Melflufen+Bortezomib+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG001","title":"A (Melflufen+Bortezomib+Dex) 40 mg"},{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone PO at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG002","title":"B (Melflufen+Daratumumab+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone PO at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG003","title":"B (Melflufen+Daratumumab+Dex) 40 mg"}],"paramType":"MEDIAN","populationDescription":"All participants in the Safety Analysis Set are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}